Approaches Beyond Classic CAR T-Cells – Module 2
Released On
March 13, 2023
Expires On
March 12, 2024
Media Type
Internet
Completion Time
30 minutes
Specialty
Hematology-Oncology
Topic(s)
Lymphoma, Oncology, Pharmacology
This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.
The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.
Credit Available
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of novel approaches to T-cell immunotherapy, particularly the development of “off-the-shelf” T-cell therapies in the management of lymphomas and other hematologic malignancies.
Learning Objective
Upon completion of this activity, participants should be better able to:
- Identify potential T-cell immunotherapeutic strategies for the treatment of lymphomas and other hematologic malignancies
Faculty
Helen E. Heslop, MD, DSc (Hon) (Chair)
Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Dan L. Duncan Chair
Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX
Helen E. Heslop, MD, DSc, is the Dan L Duncan Chair, a professor of medicine and pediatrics, and the director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s Hospital in Houston, TX. She also holds the role of the interim director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine. She received her medical training at the University of Otago School of Medicine in Dunedin, New Zealand.
Dr Heslop is a physician scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She additionally focus on reconstituting antiviral immunity post-transplant and has led an NHLBI-funded multicenter trial of allogeneic multivirus specific T cells. She has extensive experience in developing and conducting transplant studies and cell and gene therapy studies and currently holds over 20 INDs.
Dr Heslop serves as a principal investigator on several peer-reviewed research programs, including an NCI-funded SPORE in lymphoma, a Leukemia & Lymphoma Society Specialized Center of Research (SCOR) award (Immunotherapy of Lymphoma), and the Meg Vosberg Stand Up to Cancer Dream Team in T cell lymphoma. She is also the principal investigator on an NHLBI-funded training grant in Cell and Gene Therapy. Dr Heslop is a past-President of the American Society for Gene and Cell Therapy (ASGCT), the American Society of Blood and Marrow Transplant (ASBMT), and the Foundation for Accreditation of Cell Therapy (FACT). She is the past-Chair of the BMT CTN Steering Committee and is an elected member of the American Association of Physicians and the National Academy of Medicine.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Helen E. Heslop, MD, DSc, has relevant financial relationships with Allovir, Kiadis, Marker Therapeutics (Stockholder); Ankarys Therapeutics, Fresh Wind Biotechnologies, Gilead Biosciences, GSK, Immunai, Millennium, Novartis, Tessa Therapeutics (Advisor); Kuur Therapeutics, Tessa Therapeutics (Grant/Research Support).
All of the relevant financial relationships listed for this individual have been mitigated according to RMEI policies.
Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Instructions for Participation and Credit
In order to receive credit, users must:
- Read the learning objectives and faculty disclosure
- Participate in the activity
- Complete the activity evaluation
A statement of credit will be available to print immediately.
There is no fee to participate.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
If you have questions about this activity, please contact RMEI at [email protected].